How does eculizumab prevent thrombotic microangiopathy in aHUS?

ALL prescribers and dispensing sites for ULTOMIRIS or SOLIRIS MUST be certified in the new, combined ULTOMIRIS and SOLIRIS REMS. You can certify here, or; You ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... NMOSD patients receiving Soliris should be monitored for early signs of meningococcal infection. No ongoing monitoring is recommended following discontinuation ... Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ... A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ... This outcome appears to be changing in recent years with the development of eculizumab (Soliris, Alexion Phar- maceuticals, Inc), an antibody inhibitor of ... Nov 14, 2024 ... The brand names of the eculizumab biosimilars are Bekemv and Epysqli. They are only available for the treatment of PNH and aHUS in countries which have ...